|Bid||13.43 x 800|
|Ask||19.20 x 1100|
|Day's Range||15.72 - 16.30|
|52 Week Range||10.20 - 21.42|
|Beta (3Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The big shareholder groups in Kura Oncology, Inc. (NASDAQ:KURA) have power over the company. Insiders often own a...
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
climbed 6.6% to $19.71 Friday after the clinical-stage biopharmaceutical company said a phase 2 trial of its lymphoma treatment tipifarnib showed encouraging results and achieved its primary endpoint. The San Diego-based company said the results demonstrate ongoing anti-tumor activity and a manageable safety profile in advanced patients with angioimmunoblastic T-cell lymphoma (AITL) as well as non-AITL peripheral T-cell lymphoma (PTCL). "With additional follow up and new patients enrolled in the ongoing Phase 2 study, tipifarnib continues to demonstrate encouraging clinical activity in patients with relapsed or refractory PTCL who have experienced a median of three prior lines of therapy," Francine Foss, professor of medicine at the Yale Cancer Center, and a principal investigator in the trial, said in a statement.
Shares of Kura Oncology Inc. soared 27% toward a record high in premarket trading Friday, after the biopharmaceutical company announced a phase 2 trial of its lymphoma treatment achieved its primary efficacy endpoint. The stock was on track to open above its March 2, 2018 record close of $23.40. The company said the results of the trial demonstrated "ongoing anti-tumor activity and a manageable safety profile" in advanced patients with angioimmunoblastic T-cell lymphoma (AITL), as well as non-AITL relapsed or refractory peripheral T-cell lymphoma (PTCL). "We believe these data support the potential to register tipifarnib in both the AITL and PTCL-NOS patient populations, and we look forward to seeking regulatory feedback on next steps for this program," said Chief Executive Troy Wilson. The stock has run up 32% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 8% and the S&P 500 has advanced 15%.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
The San Diego-based company said it had a loss of 37 cents per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss ...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. But when you ho...
The government requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the funds’ positions on September […]
On a per-share basis, the San Diego-based company said it had a loss of 40 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Kura Oncology (KURA) is a clinical-stage biopharmaceutical company focused on advancing its research pipeline of precision medicine targeting genetically-defined hematologic malignancies and solid tumors. Kura Oncology has reported returns of 0.59%, -12.31%, -7.57%, and 37.90% in the last week, the last month, the last quarter, and the last year, respectively. The 12-month consensus analyst recommendation for Kura Oncology on September 23 is a “strong buy.” The 12-month consensus target price for Kura Oncology is $30.33, which is 77.37% higher than the company’s closing price on September 21.